USA: Business Deal Bristol-Myers Squibb Completes Divestment of Consumer Health Business
Bristol-Myers Squibb Company has completed divestment of its consumer health business UPSA to Japan-based Taisho Pharmaceutical Co. (Taisho). The move is part of Bristol-Myers’ strategy to restructure its business.
New York/USA – Bristol-Myers Squibb Company has recently announced that effective July 1, 2019 it has completed its previously announced divestment of its consumer health business, UPSA, to Taisho Pharmaceutical Co. (Taisho), the largest over-the-counter drug company in Japan.
The divestiture is part of Bristol-Myers Squibb’s strategy to simplify and to realign its business portfolio to address changes in its business and the future requirements of its evolving pipeline. UPSA is focused on delivering important consumer medicines in France, across Europe and additional countries that are outside Bristol-Myers Squibb’s core focus. The Company is focusing resources on its highest priorities of discovering, developing and delivering transformational medicines for patients facing serious diseases.
This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 46006379)